Praxis Precision Medicines, Inc. Share Price
NASDAQ: PRAX | Mid CapPraxis Precision Medicines, Inc. Stock Performance
Praxis Precision Medicines, Inc. Share Price Today
As of 20 September 2026, Praxis Precision Medicines, Inc.'s share price is $299.25. The stock opened at $308.98, compared to its previous close of $310.21. During today's trading session, Praxis Precision Medicines, Inc.'s share price traded between $296.08 and $308.98, with an average price of $302.53. Over the past 52 weeks, the stock has recorded a high of $392.31 and a low of $42.10. In terms of performance, Praxis Precision Medicines, Inc.'s share price has declined by 7.08% over the last six months and is up 464.30% on a year-on-year basis.
Praxis Precision Medicines, Inc. Share Price Chart
Praxis Precision Medicines, Inc. Quarterly Profit & Loss
All figures in USD
Praxis Precision Medicines, Inc. Annual Profit & Loss
All figures in USD
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company's platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical trial for the treatment of essential tremor; Vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; Relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020 to treat KCNT1; and PRAX-050. In addition, the company develops Elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080 that targets PCDH19-related developmental epilepsy; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.
Praxis Precision Medicines, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Sep 2026 | $352.09 | $298.92 | -18.85% |
Aug 2026 | $298.05 | $368.37 | +19.75% |
Jul 2026 | $333.60 | $307.61 | -8.22% |
Jun 2026 | $341.35 | $335.16 | -4.61% |
May 2026 | $313.27 | $351.36 | +9.82% |
Apr 2026 | $326.49 | $319.93 | -0.66% |
Mar 2026 | $330.00 | $322.05 | -4.36% |
Feb 2026 | $312.91 | $336.74 | +7.15% |
Jan 2026 | $291.22 | $314.26 | +6.45% |
Dec 2025 | $193.81 | $295.22 | +50.32% |
Nov 2025 | $183.11 | $196.40 | -1.15% |
Oct 2025 | $53.72 | $198.69 | +274.67% |